Explore RushData insights on sequence-to-data workflows, high-throughput antibody expression and characterization, binding and developability assays, and the generation of structured, AI-ready antibody data.
Discover how high-throughput wet-lab validation connects AI-designed antibody sequences to experimental data, enabling faster screening and model refinement.
Learn how AI antibody discovery connects computational design with antibody expression, binding assays, and experimental feedback for candidate selection
What makes antibody data AI/ML-ready? Explore data quality, assay metadata, and experimental validation—and plan your next dataset with Biointron RushData.
An AI-designed antibody may look promising but express poorly or bind weakly. Explore how experimental testing informs candidate selection and model refinement.
Expression conditions shape antibody screening results. Explore when CHO-derived data are useful for candidate assessment and AI model training.
A confident structure prediction does not establish antibody function. Explore experimental checks for expression, binding, and application-specific activity.
Antibody-based therapeutics, including monoclonal antibodies and antibody-drug conjugates (ADCs), represent a major and expanding class of biopharmaceuticals. ADCs are structurally complex molecules composed of a monoclonal antibody, a cytotoxic payload, and a chemical linker, designed to selectively deliver potent drugs to target cells.
You can also contact us on the Scientist and Science Exchange marketplaces.